Skip to main content
. Author manuscript; available in PMC: 2014 Dec 15.
Published in final edited form as: Clin Cancer Res. 2013 Dec 15;19(24):10.1158/1078-0432.CCR-13-1746. doi: 10.1158/1078-0432.CCR-13-1746

Figure 2. Signaling induced by PAPSS1-BRAF is more sensitive to MEK inhibition than BRAF inhibition.

Figure 2

(A) Immunoblotting of lysates from 293H cells transfected with vector (empty vector) or plasmids encoding BRAF V600E-FLAG or PAPSS1-BRAF-FLAG demonstrate that the BRAF fusion activates MAPK pathway signaling similarly to BRAF V600E. (B) While MAPK pathway signaling induced by expression of BRAF V600E is sensitive to increasing doses (0, 0.1, 0.5, 1, and 5 μmol/L) of the BRAF inhibitor vemurafenib (vem) or the MEK inhibitor trametinib (tra), signaling induced by PAPSS1-BRAF is more sensitive to trametinib than vemurafenib. kDa, kilodalton.